CN116903744B - anti-CD 73 antibody or antigen fragment thereof and application thereof - Google Patents

anti-CD 73 antibody or antigen fragment thereof and application thereof Download PDF

Info

Publication number
CN116903744B
CN116903744B CN202310739625.9A CN202310739625A CN116903744B CN 116903744 B CN116903744 B CN 116903744B CN 202310739625 A CN202310739625 A CN 202310739625A CN 116903744 B CN116903744 B CN 116903744B
Authority
CN
China
Prior art keywords
antibody
seq
antigen
amino acid
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202310739625.9A
Other languages
Chinese (zh)
Other versions
CN116903744A (en
Inventor
邱奕凯
胡桐桐
周艺
刘�东
连凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Vigorous Biotechnology Co ltd
Original Assignee
Nanjing Vigorous Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Vigorous Biotechnology Co ltd filed Critical Nanjing Vigorous Biotechnology Co ltd
Priority to CN202310739625.9A priority Critical patent/CN116903744B/en
Publication of CN116903744A publication Critical patent/CN116903744A/en
Application granted granted Critical
Publication of CN116903744B publication Critical patent/CN116903744B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Provided herein are anti-CD 73 antibodies or antigen-binding fragments thereof that specifically bind CD 73. Also provided herein are uses of the anti-CD 73 antibodies or antigen-binding fragments thereof in the treatment of tumors.

Description

anti-CD 73 antibody or antigen fragment thereof and application thereof
The present application is a divisional application of the chinese patent application No. 202210965534.2 filed on 8/12 of 2022, which is incorporated herein by reference in its entirety.
Technical Field
The present application relates to antibodies or antigen binding fragments thereof capable of specifically binding to CD73 protein and uses of such formulations. The antibodies or antigen binding fragments thereof are useful in the treatment of diseases associated with CD73 activity.
Background
The adenosine pathway can down regulate inflammation and suppress immune responses to maintain immune homeostasis. In the Tumor Microenvironment (TME), when immunogenic tumor cells die, ATP will be released into the tumor TME, followed by the cleavage of ATP to adenosine by CD39 and CD73 proteins. Abundant extracellular adenosines have immunosuppressive effects, and inhibit expansion and cytotoxicity of T cells and NK cells through A2a receptor and A2b receptor, obstruct antigen presentation of dendritic cells, and facilitate development of regulatory T cells (regulatory T cells) and myeloid-derived suppressor cells (MDSCs) (reference 1).
The breakdown of extracellular ATP is mediated by the CD39/CD73 cascade, with CD39 catalyzing the conversion of ATP to AMP and CD73 catalyzing the conversion of AMP to adenosine. The higher concentration of adenosine detected in solid tumors than surrounding tissues suggests its role in suppressing immune responses in TME and tumor progression. Cell surface CD73 protein and soluble CD73 directly break down AMP into adenosine, and CD73 thus becomes a hot spot target for tumor therapy. CD73 is expressed by induction in hypoxia (HIFa), inflammation (tgfβ) and chemotherapy-induced cell death. It responds directly to hifα signaling, which may explain why tumor cells have increased CD73 expression in hypoxic conditions (reference 2). The TGFb signal stabilizes the H1fα protein and indirectly enhances CD73 expression. CD73 is also expressed on Treg, cd4+ memory T cells, and is used in particular to label Th17 surface proteins.
Immunosuppression of the CD73 adenosine pathway in TMEs has received high attention over the last 10 years. The therapeutic potential of CD73 antibodies has been demonstrated in preclinical studies (reference 3) and clinical trials are underway. Ollecumab (MEDI 9447) is the anti-CD 73 monoclonal antibody, the first anti-CD 73 antibody drug in clinical trial 2. Ollecumab alleviates adenosine-mediated immunosuppression in vitro and in vivo in CT26 syngeneic animal models. 10mg/kg Ollecumab inhibited tumor growth by 50% and showed a substantial increase in CD8+ cytotoxic T lymphocytes in TIL (tumor infiltrating lymphocytes). Treatment with the binding PD-1 antibody, the combined administration of Ollecumab and PD-1 antibody has additive effect on tumor rejection in mice, and can increase secretion of IFNgamma and TNF alpha by T cells. It is therefore possible to combine anti-CD 73 antibodies with other immune checkpoint blockers in cancer treatment. Other CD73 antibody drugs in clinical phase one trials included BMS-986179 of precious group of bepotash, CPI-006 of Corvus pharmaceutical company (Corvus Pharmaceuticals inc.) (reference 4), bispecific antibody GS-1423 of Gilead Sciences and AK119 of akoso, most of which were combined with other immune checkpoint blockers such as PD-1, PD-L1 or CTLA-4 in clinical trials (reference 1).
Disclosure of Invention
In one aspect, provided herein is an isolated antibody or antigen binding fragment thereof comprising:
i) A heavy chain variable domain (VH) comprising:
1) Heavy chain CDR1 (HCDR 1) comprising an amino acid sequence selected from one of SEQ ID NOs 2, 10, 18, 26, 34, 42, 50, 58, 66, 74 and 82;
2) Heavy chain CDR2 (HCDR 2) comprising an amino acid sequence selected from one of SEQ ID NOs 3, 11, 19, 27, 35, 43, 51, 59, 67, 75 and 83; and
3) Heavy chain CDR3 (HCDR 3) comprising an amino acid sequence selected from one of SEQ ID NOs 4, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84 and 105; and
II) a light chain variable domain (VL), comprising:
1) Light chain CDR1 (LCDR 1) comprising an amino acid sequence selected from one of SEQ ID NOs 6, 14, 22, 30, 38, 46, 54, 62, 70, 78 and 86;
2) Light chain CDR2 (LCDR 2) comprising an amino acid sequence selected from one of SEQ ID NOs 7, 15, 23, 31, 39, 47, 55, 63, 71, 79 and 87; and
3) Light chain CDR3 (LCDR 3) comprising an amino acid sequence selected from one of SEQ ID NOS: 8, 16, 24, 32, 40, 48, 56, 64, 72, 80 and 88,
wherein the antibody or antigen binding fragment thereof is capable of specifically binding to CD73, preferably human CD73.
In some embodiments, 1) the VH comprises HCDR1, HCDR2 and HCDR3 having the sequences of SEQ ID NOs 18, 19 and 20 respectively, and the VL comprises LCDR1, LCDR2 and LCDR3 having the sequences of SEQ ID NOs 22, 23 and 24 respectively; 2) The VH comprises HCDR1, HCDR2 and HCDR3 with sequences shown as SEQ ID NO 34, 35 and 36 respectively, and the VL comprises LCDR1, LCDR2 and LCDR3 with sequences shown as SEQ ID NO 38, 39 and 40 respectively; 3) The VH comprises HCDR1, HCDR2 and HCDR3 with sequences shown as SEQ ID NO. 2, 3 and 4 respectively, and the VL comprises LCDR1, LCDR2 and LCDR3 with sequences shown as SEQ ID NO. 6, 7 and 8 respectively; 4) The VH comprises HCDR1, HCDR2 and HCDR3 with sequences shown in SEQ ID NO 10, 11 and 12 respectively, and the VL comprises LCDR1, LCDR2 and LCDR3 with sequences shown in SEQ ID NO 14, 15 and 16 respectively; 5) The VH comprises HCDR1, HCDR2 and HCDR3 with sequences shown in SEQ ID NO 26, 27 and 28 respectively, and the VL comprises LCDR1, LCDR2 and LCDR3 with sequences shown in SEQ ID NO 30, 31 and 32 respectively; 6) The VH comprises HCDR1, HCDR2 and HCDR3 with sequences shown as SEQ ID NO. 42, 43 and 44 respectively or HCDR1, HCDR2 and HCDR3 with sequences shown as SEQ ID NO. 42, 43 and 105 respectively, and the VL comprises LCDR1, LCDR2 and LCDR3 with sequences shown as SEQ ID NO. 46, 47 and 48 respectively; 7) The VH comprises HCDR1, HCDR2 and HCDR3 with sequences shown as SEQ ID NO. 50, 51 and 52 respectively, and the VL comprises LCDR1, LCDR2 and LCDR3 with sequences shown as SEQ ID NO. 54, 55 and 56 respectively; 8) The VH comprises HCDR1, HCDR2 and HCDR3 with sequences shown in SEQ ID NOs 58, 59 and 60 respectively, and the VL comprises LCDR1, LCDR2 and LCDR3 with sequences shown in SEQ ID NOs 62, 63 and 64 respectively; 9) The VH comprises HCDR1, HCDR2 and HCDR3 with sequences shown as SEQ ID NO. 66, 67 and 68 respectively, and the VL comprises LCDR1, LCDR2 and LCDR3 with sequences shown as SEQ ID NO. 70, 71 and 72 respectively; 10 The VH includes HCDR1, HCDR2 and HCDR3 having the sequences shown in SEQ ID NOS 74, 75 and 76, respectively, and the VL includes LCDR1, LCDR2 and LCDR3 having the sequences shown in SEQ ID NOS 78, 79 and 80, respectively; or 11) the VH comprises HCDR1, HCDR2 and HCDR3 having the sequences shown in SEQ ID NOS 82, 83 and 84, respectively, and the VL comprises LCDR1, LCDR2 and LCDR3 having the sequences shown in SEQ ID NOS 86, 87 and 88, respectively.
In some embodiments, the VH comprises an amino acid sequence having at least 80% identity to a sequence selected from one of SEQ ID NOs 1, 9, 17, 25, 33, 41, 49, 57, 65, 73 and 81, and the VL comprises an amino acid sequence having at least 80% identity to a sequence selected from one of SEQ ID NOs 5, 13, 21, 29, 37, 45, 53, 61, 69, 77 and 85.
In some embodiments, the VH comprises an amino acid sequence selected from one of SEQ ID NOs 1, 9, 17, 25, 33, 41, 49, 57, 65, 73 and 81 or a variant comprising up to 3 amino acid substitutions relative to the amino acid sequence of one of SEQ ID NOs 1, 9, 17, 25, 33, 41, 49, 57, 65, 73 and 81, and the VL comprises an amino acid sequence selected from one of SEQ ID NOs 5, 13, 21, 29, 37, 45, 53, 61, 69, 77 and 85 or a variant comprising up to 3 amino acid substitutions relative to the amino acid sequence of one of SEQ ID NOs 5, 13, 21, 29, 37, 45, 53, 61, 69, 77 and 85.
In some embodiments, 1) the VH comprises the amino acid sequence shown in SEQ ID NO. 17 and the VL comprises the amino acid sequence shown in SEQ ID NO. 21; 2) The VH comprises an amino acid sequence shown as SEQ ID NO. 33, and the VL comprises an amino acid sequence shown as SEQ ID NO. 37; 3) The VH comprises an amino acid sequence shown in SEQ ID NO. 1, and the VL comprises an amino acid sequence shown in SEQ ID NO. 5; 4) The VH comprises an amino acid sequence shown as SEQ ID NO. 9, and the VL comprises an amino acid sequence shown as SEQ ID NO. 13; 5) The VH comprises an amino acid sequence shown as SEQ ID NO. 25, and the VL comprises an amino acid sequence shown as SEQ ID NO. 29; 6) The VH comprises an amino acid sequence shown as SEQ ID NO. 41, and the VL comprises an amino acid sequence shown as SEQ ID NO. 45; 7) The VH comprises an amino acid sequence shown as SEQ ID NO. 49, and the VL comprises an amino acid sequence shown as SEQ ID NO. 53; 8) The VH comprises an amino acid sequence shown as SEQ ID NO. 57, and the VL comprises an amino acid sequence shown as SEQ ID NO. 61; 9) The VH comprises an amino acid sequence shown as SEQ ID NO. 65, and the VL comprises an amino acid sequence shown as SEQ ID NO. 69; 10 The VH comprises an amino acid sequence shown as SEQ ID NO. 73, and the VL comprises an amino acid sequence shown as SEQ ID NO. 77; or 11) the VH comprises the amino acid sequence shown in SEQ ID NO. 81, and the VL comprises the amino acid sequence shown in SEQ ID NO. 85.
In some embodiments, the antibody or antigen binding fragment thereof has an enzymatic activity of 10 against the CD73 expressed by the cell surface -1 Mu g/mL to 10 -3 μg/mL IC 50 Values.
In some embodiments, the antibody or antigen binding fragment thereof binds to EC of cells expressing the CD73 50 A value of 1. Mu.g/mL to 10 -2 μg/mL。
In some embodiments, the antibody is a murine antibody, chimeric antibody, humanized antibody, or human antibody.
In some embodiments, the antibody or antigen binding fragment thereof is a monoclonal antibody, scFv, fab, fab ', (Fab') 2 Or Fv.
In some embodiments, the VH of the humanized antibody comprises an amino acid sequence selected from SEQ ID NO 91, 93, 89, 95, 97, 99 or 101 and the VL of the humanized antibody comprises an amino acid sequence selected from SEQ ID NO 92, 94, 90, 96, 98, 100 or 102.
In some embodiments, 1) the VH comprises the amino acid sequence shown as SEQ ID NO. 91 and the VL comprises the amino acid sequence shown as SEQ ID NO. 92; 2) The VH comprises an amino acid sequence shown as SEQ ID NO. 93 and the VL comprises an amino acid sequence shown as SEQ ID NO. 94; 3) The VH comprises an amino acid sequence shown as SEQ ID NO. 89 and the VL comprises an amino acid sequence shown as SEQ ID NO. 90; 4) The VH comprises an amino acid sequence shown in SEQ ID NO. 95 and an amino acid sequence shown in VLSEQ ID NO. 96; 5) The VH comprises an amino acid sequence shown as SEQ ID NO. 97 and the VL comprises an amino acid sequence shown as SEQ ID NO. 98; 6) The VH comprises an amino acid sequence shown as SEQ ID NO. 99 and the VL comprises an amino acid sequence shown as SEQ ID NO. 100; or 7) the VH comprises the amino acid sequence shown in SEQ ID NO. 101 and the VL comprises the amino acid sequence shown in SEQ ID NO. 102.
In some embodiments, the humanized antibody has 10 for enzymatic activity of expressing the CD73 expressed by the cell surface -1 Mu g/mL to 10 -2 μg/mL IC 50 Values.
In some embodiments, the antibody or antigen binding fragment thereof binds to CD73 with a KD value of 10 -8 M to 10 -11 M。
In some embodiments, the VH and/or VL are linked to a constant region of an immunoglobulin; preferably, the VH is linked to an IgG1 constant region.
In another aspect, provided herein are bispecific antibodies, the antibodies described above, or antigen-binding fragments thereof, and a second antibody portion.
In some embodiments, the second antibody moiety is capable of binding an antigen other than CD 73.
In some embodiments, the antigen other than CD73 is CD39, CTLA-4, PD-L1, TIM-3, LAG-3 or A2aR.
In some embodiments, the second antibody moiety is Fab, fab ', (Fab') 2 Fv, scFv or sdAb.
In another aspect, provided herein are polynucleotides encoding the antibodies or antigen-binding fragments thereof or bispecific antibodies of claim above.
In another aspect, provided herein are vectors of the polynucleotides described above.
In another aspect, provided herein are cells comprising the polynucleotides or vectors described above.
In another aspect, provided herein is a pharmaceutical composition for use in the treatment of cancer, comprising: the above antibody or antigen-binding fragment thereof, or the above bispecific antibody; and a pharmaceutically acceptable carrier.
In some embodiments, the pharmaceutical composition further comprises one or more additional anticancer agents.
In some embodiments, the cancer is a solid cancer.
In some embodiments, the cancer is selected from non-small cell lung cancer (NSCLC), triple Negative Breast Cancer (TNBC), or pancreatic cancer.
In another aspect, provided herein is the use of an antibody or antigen-binding fragment thereof, bispecific antibody, polynucleotide, vector or cell comprising the above for the manufacture of a medicament for the treatment of cancer.
In some embodiments, the cancer is a solid cancer.
In some embodiments, the cancer is selected from non-small cell lung cancer, triple negative breast cancer, or pancreatic cancer.
In yet another aspect, provided herein is a method of treating a disease comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof, bispecific antibody, or pharmaceutical composition as described above.
In some embodiments, the subject is a human.
In some embodiments, the disease is cancer. In some preferred embodiments, the disease is a solid cancer. In a more preferred embodiment, the solid cancer is selected from non-small cell lung cancer (NSCLC), triple Negative Breast Cancer (TNBC) or pancreatic cancer.
In the present invention we identified 11 antibodies, 8 antibodies with superior ability to antagonize CD73 extracellular-5' -nucleotidase than MEDI9447 and a high diversity in multi-epitope targeting. According to the high expression level of CD73 in various tumor tissues (reference 5, reference 6), these antibody precursors have high potential in tumor treatment, and have a wide range of indications including non-small cell lung cancer (NSCLC), triple Negative Breast Cancer (TNBC), pancreatic cancer, and the like. At the same time, anti-CD 73 antibodies have a high degree of flexibility in combination therapy, including PD-1, PD-L1, chemotherapy, A2AR antagonists, and the like.
According to the function of CD73 in immunoregulation and the high expression and high adenosine concentration of CD73 in tumor cells, the invention can reduce the immunosuppression of an adenosine pathway on the tumor microenvironment by blocking the activity of CD73 enzyme by the anti-CD 73 antibody, and is beneficial to the specific killing effect of T cells and NK cells on tumors.
In the present invention, we identified antibodies that have superior ability to antagonize CD73 extracellular-5' -nucleotidase than MEDI9447 and have a high diversity in multi-epitope targeting. These antibody precursors can provide good candidates for antibody therapy, bispecific antibody design, and combination therapy with chemotherapy and radiation therapy.
Drawings
Fig. 1:52A6B3 and 100C5A3 inhibit AMP hydrolysis.
Fig. 2:52A8B3, 96A5A5 and 134D2H6 inhibit AMP hydrolysis.
Fig. 3:141G7E9, 143H3C5 and 143E5D2 inhibit AMP hydrolysis.
Fig. 4: inhibition of AMP hydrolysis by 9E12E3, 22E1B4 and 35D8G 8.
Fig. 5: FACS data of anti-CD 73 mouse monoclonal antibody binding to human CD73-CHO-K1 cell line.
Fig. 6: inhibition of CD 73-mediated AMP hydrolysis by 7 humanized antibodies, (a) inhibition of CD 73-mediated AMP hydrolysis by 5 humanized antibodies; (B) Inhibition of CD 73-mediated AMP hydrolysis was another 2 humanized antibodies.
Detailed Description
The present disclosure provides anti-CD 73 monoclonal antibodies and uses thereof. The present disclosure relates to the amino acid sequences of the heavy chain variable domain (VH) and the light chain variable domain (VL) of mouse anti-CD 73 monoclonal antibodies (9E 12E3, 22E1E4, 35D8G8, 52A8B3, 52A6B3, 96A5, 100C5A3, 134D2H6, 141G7E9, 143E5D2, and 143H3C5 clones). It also relates to the amino acid sequences of the heavy chain variable domain (VH) and the light chain variable domain (VL) that are humanized or post-translationally modified on these mouse anti-CD 73 monoclonal antibody clones. The disclosure also relates to methods of producing anti-CD 73 monoclonal antibodies.
The present disclosure provides anti-human CD73 chimeric antibodies by fusing the variable regions of the heavy and light chains of the disclosed mouse anti-CD 73 monoclonal antibodies to the constant regions of human IgG. The invention provides humanized versions of the heavy chain variable domain (VH) and the light chain variable domain (VL) of a mouse anti-CD 73 monoclonal antibody. In some examples, the CDRs of a mouse anti-CD 73 monoclonal antibody are grafted onto a human IgG framework sequence, and the resulting humanized variable domains may be further fused to the constant regions of human IgG.
Definition of the definition
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.
The term "or" refers to a single element of a list of selectable elements unless the context clearly indicates otherwise. The term "and/or" means any one, any two, any three, any more, or all of the listed selectable elements.
The term "about" as used herein means a value within + -10% of a given numerical value.
The terms "comprising," "including," "having," and similar referents used herein do not exclude the presence of unrecited elements. These terms also include cases consisting of only the recited elements.
"antibody" refers to an immunoglobulin secreted by plasma cells (effector B cells) and used by the body's immune system to neutralize foreign substances (polypeptides, viruses, bacteria, etc.). The foreign substance is correspondingly referred to as an antigen. The basic structure of classical antibody molecules is a 4-mer consisting of 2 identical heavy chains and 2 identical light chains. Heavy and light chains are divided into a variable region (V) at the amino terminus and a constant region (C) at the carboxy terminus according to the conservative differences in amino acid sequences. The variable regions of a heavy chain and a light chain interact to form an antigen binding site (Fv). In the variable region, the composition and order of amino acid residues in certain regions are more variable than in other regions within the variable region (framework regions, FRs), known as hypervariable regions (HVRs), which are actually key sites for binding of antibodies to antigens. Because these hypervariable region sequences are complementary to an epitope, they are also known as complementarity-determining region (CDR). The heavy and light chains each have three complementarity determining regions, referred to as HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2, LCDR3, respectively. The amino acid sequence of the CDRs can be determined using art-recognized numbering schemes, such as Kabat, chothia, IMGT, abM or Contact numbering schemes. In a specific embodiment, the CDR sequences of the antibodies described herein have been determined according to the Kabat numbering scheme. Antibodies can be divided into five main different types based on the amino acid sequence of the heavy chain constant region of the antibody: igA, igD, igE, igG and IgM. These antibody types can be further classified into subclasses according to the size of the hinge region, the position and molecular weight of the inter-chain disulfide bond, for example, igGl, igG2a, igG2b, igG3, and the like. Light chains can be classified into two types, kappa and lambda, depending on the amino acid composition and arrangement of the antibody light chain constant region. Subunit structures and three-dimensional conformations of different classes of immunoglobulins are known in the art.
An "antigen-binding fragment" of an antibody molecule refers to a fragment of an antibody molecule of amino acids involved in antigen-specific binding, e.g., fab ', (Fab') 2 scFv, sdAb, and the like. Those skilled in the art know how to obtain such antigen binding fragments. For example, classical antibody molecules mayDigesting with papain to obtain Fab fragment, and digesting with pepsin to obtain F (ab') 2 Disconnection of F (ab') by treatment with a reducing agent 2 Disulfide bonds between the hinge regions form Fab' fragments.
A single chain antibody (single chain fragment variable, scFv) is composed of an antibody heavy chain variable region and a light chain variable region which are linked together by a short peptide to form a single peptide chain. By correct folding, the variable regions from the heavy and light chains interact through non-covalent bonds to form Fv fragments, so that scfvs can better retain their affinity for antigen.
"Single domain antibody (single domain antibody, sdAb)", or also referred to as "VHH antibody", refers to an antibody molecule that has antigen binding capacity, including a heavy chain variable region without a light chain. Structurally, a single domain antibody can also be considered an antigen binding fragment of an antibody molecule. It was first found in camelids, and then researchers screened through antibody libraries (e.g., phage display libraries) to find more single domain antibodies with antigen binding capacity. Single domain antibodies have several advantages over common antibody molecules (e.g., classical tetrameric antibody molecules) or antigen-binding fragments thereof, including, for example, but not limited to: the molecular weight is smaller, so that the antibody can easily reach tissues or parts which are difficult to reach by common antibody molecules when being used for a human body, or can contact antigen epitopes which are difficult to reach by the common antibody molecules in proteins or polypeptides; more stable and able to withstand, for example, changes in temperature and pH, and the action of denaturants and proteases.
"Fc fragment" refers to the handle region of a Y "shaped antibody molecule, i.e., the crystallizable fragment (fragment crystallizable, fc) comprises the second and third constant domains (CH 2 and CH3 domains) of the heavy chain. The antibody Fc region can be obtained by hydrolyzing an antibody molecule with a proteolytic enzyme such as papain. In some examples, the Fc region may comprise a hinge, CH2, and CH3. Dimerization between two Fc-containing polypeptides may be mediated when the Fc region comprises a hinge. The Fc fragment may be from IgG, igM, igD, igE or IgA. In some examples, the Fc region is from IgG1, igG2, igG3, or IgG4."Fc fragment" also includes variant Fc fragments derived from natural Fc fragments, which have been altered but still retain their effector function. A "variant Fc fragment" comprises an amino acid sequence having at least one amino acid change in the amino acid sequence of the native Fc fragment. In some examples, the variant Fc-fragment has at least one amino acid substitution compared to the parent Fc-fragment (native Fc-fragment), e.g., about 1 to about 10 amino acids are substituted, and preferably about 1 to about 5 amino acid substitutions, in the parent Fc-fragment. In some examples, the variant Fc-fragment Fc-region has at least about 80% sequence identity, at least about 90% sequence identity, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the parent Fc-fragment. The effector functions of an "Fc fragment" may include binding to Fc receptors, clq binding and Complement Dependent Cytotoxicity (CDC), antibody dependent cell-mediated cytotoxicity (ADCC), mediated phagocytosis, and the like. In some cases, the Fc fragment may be optionally engineered to enhance, attenuate, or eliminate its effector function.
"murine antibody" refers to an antibody in which the variable and constant regions, if any, are derived from mouse or rat immunoglobulin sequences. The murine antibody can be conveniently obtained by immunizing a mouse or rat with the corresponding antigen and isolating the antibody of interest therefrom. Alternatively, it can be obtained by isolating and culturing cells expressing the antibody of interest (e.g., B cells) after immunization of mice or rats with the corresponding antigen. Alternatively, after a mouse or a rat is immunized with the corresponding antigen, cells expressing the antibody of interest are isolated and cultured, and fused with immortalized cells such as myeloma cells to obtain hybridoma cells, and the hybridoma cells are cultured to obtain the antibody of interest (e.g., monoclonal antibody) in a long term and in a large amount. In some embodiments, the "murine antibody" is a mouse antibody.
"humanized antibody" refers to a chimeric antibody obtained by artificial engineering a non-human antibody, i.e., an antibody whose variable and constant regions (if any) are not derived from human immunoglobulin, so as to contain the amino acid sequence of a human antibody. The humanized antibody may comprise constant and/or framework regions of a human antibody. Humanized antibodies can be obtained by genetic engineering means, for example, replacing the constant region of a murine antibody with that of a human antibody and/or replacing the framework region of a murine antibody with that of a human antibody. Such humanized modifications generally do not affect the binding specificity of the original antibody to the corresponding antigen and thus such antigens are also included within the scope of the present invention.
"human antibody" or "humanized antibody" refers to an antibody in which both the variable and constant regions, if any, are derived from human germline immunoglobulin sequences. Human antibodies can be obtained by a variety of techniques including phage antibody library techniques, single B cell cloning techniques, transgenic mouse techniques (e.g., using transgenic mice that have introduced human germline immunoglobulin genes and removed mouse own germline immunoglobulin genes), and the like. Human antibodies have the advantage of being less immunogenic and safer when used in human patients than antibodies of animal origin (e.g., murine antibodies).
The term "monoclonal antibody" as used herein refers to a homogeneous antibody directed against only one specific epitope. In contrast to polyclonal antibodies, which typically include different antibodies directed against different epitopes, each monoclonal antibody is directed against a single epitope on the antigen. The modifier "monoclonal" refers to a homogeneous characteristic of the antibody and is not to be construed as requiring production of the antibody by any particular method. Monoclonal antibodies of the invention may be produced by hybridoma methods or recombinant DNA methods well known in the art, or may be obtained by screening methods described elsewhere herein.
An "isolated" antibody is an antibody that has been isolated and/or recovered from its natural environment or production environment (e.g., cell culture). Contaminating components in the production environment, such as components from recombinantly transfected cells (e.g., enzymes, hormones, and other proteinaceous or nonprotein components, nucleic acids) often interfere with research, diagnostic, or therapeutic uses of the antibodies. Thus, preferably, the isolated antibody is substantially unrelated to other components in its natural or production environment.
An "epitope" refers to the portion of a molecule (e.g., an antigen) that binds to an antibody. An epitope may comprise a non-contiguous portion of the molecule (e.g., an amino acid residue in a polypeptide that is not contiguous over the major sequence of the polypeptide, but is sufficiently close to each other in the trivalent and tetravalent structures of the polypeptide to be bound by an antibody).
"bispecific antibody" refers to an antibody molecule having two different binding sites that can recognize and bind to two different antigens, respectively. In one embodiment, one binding site of the bispecific antibody can be used to bind immune cells (e.g., T cells), and the other binding site can be used to bind tumor cells, thereby enhancing the killing effect of immune cells on tumor cells while reducing side effects such as off-target toxicity. In another embodiment, the two binding sites of the bispecific antibody bind to a protein or antigen (e.g.CD73 and PD-L1), respectively, associated with tumor microenvironment and immunosuppression. Such bifunctional antibodies generally have higher therapeutic effects as drugs for treating tumors than monoclonal antibodies. Similarly, antibody molecules can be engineered to include multiple different binding sites, generating "trispecific antibodies", "tetraspecific antibodies", and the like. As used herein, "multispecific antibodies" encompass such bispecific antibodies, trispecific antibodies, tetraspecific antibodies, and the like.
"fusion protein" refers to a protein molecule made up of at least two different peptide fragments that is produced by man (e.g., by genetic engineering techniques). These peptide fragments do not exist in nature or in the same protein molecule. Examples of common fusion proteins including antibody fragments include chimeric antibodies, antibody-cytokine fusion proteins, antibody-cytotoxin fusion proteins (also known as immunotoxins), enzyme-labeled antibodies for immunodetection, chimeric Antigen Receptors (CARs), and the like.
"targeting" or "specific binding" refers to the fact that one molecule (e.g., an antibody or antigen binding fragment thereof) has a higher binding affinity for another molecule (e.g., a tumor cell surface antigen) than the other molecules that are concurrently present in the environment. "targeting" or "specific binding" does not exclude that the molecule may have binding affinity for more than one molecule, e.g. a bispecific antibody may have high affinity for two different antigens.
EC 50 (concentration for 50%of maximal effect) means a concentration causing 50% of the maximum effect. In FACS for the expression of the binding capacity of an antibody molecule to a corresponding antigen on a cell, this can mean the generation of maximum fluorescenceAntibody molecule concentration at half light intensity. The lower the EC50 value, the greater the binding affinity to the antigen on the cell.
KD values can also be used to measure the binding affinity of an antibody to its antigen. KD is the equilibrium dissociation constant between an antibody and its antigen, i.e., k off /k on Is a ratio of (2). Thus the lower the KD value (lower concentration), the higher the affinity of the antibody.
The inhibitory effect of an inhibitor on the biological activity of an active molecule can be achieved by IC 50 The value (half maximal inhibitory concentration) is measured. IC (integrated circuit) 50 Indicating what inhibitor concentration is required to inhibit the activity (e.g., catalyze the conversion of AMP to adenosine) of the active molecule (e.g., CD 73) by half. IC (integrated circuit) 50 The smaller the value, the more inhibitory it is against the active molecule.
"variant" refers to a product sequence (e.g., a CDR sequence, VH or VL sequence) that results from introducing a difference in amino acid sequence relative to a reference sequence (e.g., a CDR sequence, VH or VL sequence disclosed herein). It will be appreciated by those skilled in the art that, based on the specific sequences provided herein, the corresponding variants of the CD 73-targeting antibodies or antigen binding fragments thereof provided herein may be obtained by substitution, deletion, addition and validation or screening of a few amino acids for the binding capacity or inhibition capacity of the resulting product to the corresponding antigen CD73, and are intended to be included within the scope of the present invention. For example, an antibody or antigen binding fragment thereof disclosed herein may have at least 1 and no more than 10, or no more than 5, 4, 3, 2, or 1 amino acid change over the full length or CDR sequence.
"purification tag" refers to an amino acid sequence expressed together with a protein or polypeptide of interest in the form of a fusion protein for purification of the protein or polypeptide of interest, including but not limited to His6 tag, flag tag, MBP (maltose binding protein) tag, GST (glutathione-transferase) tag, SUMO (small ubiquitin related modifier (small ubiquitin related modifier)), and the like. These tags may be removed enzymatically after purification or may be used with tags (e.g., his6 tags) without affecting the normal function of the protein or polypeptide of interest.
"detectable tag" refers to an amino acid sequence or other chemical group attached to a protein or polypeptide for use in indicating the presence or amount of the protein or polypeptide in a sample, or for tracking positional information of the protein or polypeptide in a subject or within a cell. Examples of detectable labels include various enzymes that can be used in immunoassays, such as horseradish peroxidase (HRP), alkaline phosphatase (ALP); a fluorescent group (e.g., FAM, FITC) or a fluorescent protein (e.g., GFP); radioisotopes (e.g 3 H、 14 C、 35 S). When the detectable label is an enzyme, the presence or amount of the protein or polypeptide linked to the enzyme can be determined by the enzymatic activity of the enzyme.
The terms "nucleic acid molecule", "nucleic acid" and "polynucleotide" are used interchangeably herein to refer to a polymer of nucleotides. Such nucleotide polymers may contain natural and/or unnatural nucleotides and include, but are not limited to, DNA, RNA, and PNA. "nucleic acid sequence" refers to a linear sequence of nucleotides contained in a nucleic acid molecule or polynucleotide.
The term "vector" refers to a nucleic acid molecule (e.g., a nucleic acid, plasmid, virus, etc.) that can be engineered to contain a polynucleotide of interest (e.g., a coding sequence for a polypeptide of interest) or that can replicate in a host cell. The carrier may include one or more of the following components: an origin of replication, one or more regulatory sequences (such as promoters and/or enhancers) that regulate the expression of the polynucleotide of interest, and/or one or more selectable marker genes (such as an antibiotic resistance gene and a gene useful in colorimetric assays, e.g., β -galactose). The term "expression vector" refers to a vector used to express a polypeptide of interest in a host cell.
"host cell" refers to a cell that may be or have been a vector or recipient of an isolated polynucleotide. The host cell may be a prokaryotic cell or a eukaryotic cell. Exemplary eukaryotic cells include mammalian cells, such as primate or non-primate cells; fungal cells such as yeast; a plant cell; insect cells. Non-limiting exemplary mammalian cells include, but are not limited to NSO cells, 293 and CHO cells, as well as derived cells thereof, such as 293-6E, CHO-DG44, CHO-K1, CHO-S and CHO-DS cells. Host cells include the progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation. Host cells also include cells transfected in vivo with the nucleic acid molecules or expression vectors provided herein.
"treatment" refers to the treatment of a subject to obtain beneficial or desired clinical results. As used herein, "treatment" encompasses a variety of treatments, including administration of any possible drug to a subject, surgery, radiation, and the like. For the purposes of the present invention, beneficial or desired clinical results include, but are not limited to, any one or more of the following: alleviating one or more symptoms, attenuating the extent of a disease, preventing or delaying the spread of a disease (e.g., metastasis, such as to the lung or lymph node), preventing or delaying the recurrence of a disease, delaying or slowing the progression of a disease, ameliorating a disease condition, inhibiting the progression of a disease or disease, blocking its progression and remission (whether partial or complete remission). The methods provided herein encompass any one or more of these therapeutic aspects. In light of the above, "treating" does not require complete removal of all symptoms of the condition or disease or complete alleviation.
The term "therapeutically effective amount" refers to an amount of an active compound that is sufficient to elicit the biological or medical response desired by the clinician in the subject. The "therapeutically effective amount" of the fusion protein of the present invention may be determined by one skilled in the art depending on the route of administration, the weight, age, condition of the subject, and the like. For example, typical daily dosages may range from 0.01mg to 100mg or more of active ingredient per kg body weight.
"solid cancer (or solid tumor)" refers to a tangible tumor that can be detected by imaging examination methods such as CT, magnetic resonance, and the like. Examples of solid tumors include gastric cancer, lung cancer, colorectal cancer, pancreatic cancer, breast cancer, liver cancer, and the like.
The term "pharmaceutically acceptable carrier" as used in reference to pharmaceutical compositions refers to substances such as solid or liquid diluents, fillers, antioxidants, stabilizers and the like which may be safely administered and which are suitable for administration to humans and/or animals without undue adverse side effects, while maintaining the viability of the drug or active agent located therein. Depending on the route of administration, a variety of different carriers well known in the art may be used including, but not limited to, sugars, starches, cellulose and its derivatives, maltose, gelatin, talc, calcium sulfate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffers, emulsifying agents, isotonic saline, and/or pyrogen-free water and the like. The pharmaceutical composition provided herein can be prepared into clinically acceptable dosage forms such as powder, injection and the like. The pharmaceutical compositions of the invention may be administered to a subject using any suitable route, for example, by oral, intravenous infusion, intramuscular injection, subcutaneous injection, intraperitoneal, rectal, sublingual, or via inhalation, transdermal, etc.
"subject" refers to an animal, such as a mammal, including, but not limited to, humans, rodents, apes, felines, canines, equines, bovines, porcines, sheep, goats, mammalian laboratory animals, mammalian farm animals, mammalian sports animals, and mammalian pets. The subject may be male or female and may be any suitable-aged subject, including infant, young, adult, and geriatric subjects. In some examples, a subject refers to an individual in need of treatment for a disease or disorder. In some examples, the subject receiving treatment may be a patient who has, or is at risk of developing, a disorder associated with the treatment. In other examples, the subject is a healthy individual or an individual with a disease of no interest. In a particular example, the subject is a human, such as a human patient. The term is generally used interchangeably with "patient," "test subject," "treatment subject," and the like.
When referring to amino acid or nucleotide sequences, the term "sequence identity (sequence identity)" (also referred to as "sequence identity") refers to the amount of degree of identity between two amino acid or nucleotide sequences (e.g., a query sequence and a reference sequence), typically expressed as a percentage. Typically, sequence alignment (alignment) is performed and gaps (gaps), if any, introduced prior to calculating the percent identity between two amino acid or nucleotide sequences. If at a certain alignment the amino acid residues or bases in the two sequences are identical, then the two sequences are considered to be identical or matched at that position; amino acid residues or bases in the two sequences differ, and are considered to be inconsistent or mismatched at that position. In some algorithms, the number of matching positions is divided by the total number of positions in the alignment window to obtain sequence identity. In other algorithms, the number of gaps and/or the gap length are also considered. For the purposes of the present invention, the disclosed alignment software BLAST (found in the webpage ncbi.nlm.nih.gov) can be used to obtain optimal sequence alignment by using default settings and calculate sequence identity between two amino acid or nucleotide sequences.
"CD73", also known as extracellular-5 '-nucleotidase (ecto-5' -NT or EC 3.1.3.5), is a cell surface phosphatase that catalyzes the dephosphorylation of extracellular AMP to produce adenosine. Physiologically, CD73 is induced by hypoxia to control inflammation at the site of injury. Pathologically, CD73 is often found to be overexpressed on regulatory T cells (Tregs) and tumor cells. The increase in CD73 activity results in the accumulation of adenosine in the Tumor Microenvironment (TME). Adenosine inhibits innate and adaptive immunity by binding to adenosine receptors A2a and A2b by modulating many immune cells, such as macrophages, dendritic cells, natural killer cells and T effector cells. Thus, it is speculated that immunosuppression of adenosine may be alleviated by inhibiting the activity of CD73 in TME. In fact, in vivo animal studies have shown that inhibition of CD73 activity can inhibit tumor formation and growth, suggesting that CD73 is a promising target for cancer treatment. The term "human CD73" refers to CD73 derived from a human. An exemplary amino acid sequence of human CD73 is represented in GenBank accession No. P21589.1.
In some embodiments, an anti-CD 73 monoclonal antibody of the present disclosure may cross-react with CD73 of a species other than human or with other proteins structurally related to human CD73. In some embodiments, the anti-CD 73 monoclonal antibodies provided herein are fully specific for human CD73, and do not exhibit species or other types of cross-reactivity.
anti-CD 73 antibodies or antigen binding fragments thereof
Provided herein are anti-CD 73 antibodies or antigen-binding fragments thereof that specifically bind CD 73. The anti-CD 73 antibody or antigen-binding fragment thereof binds to the CD73 molecule with a relatively high binding affinity. The ability of an anti-CD 73 antibody or antigen binding fragment thereof to bind to CD73 can be measured by assay methods such as enzyme-linked immunosorbent assay (ELISA) and flow cytometry fluorescence sorting (FACS), as set forth in the examples below. In addition, it can also be determined by other protein interaction assay methods known in the art, such as Surface Plasmon Resonance (SPR), biological Layer Interference (BLI) techniques. The anti-CD 73 antibody or antigen-binding fragment thereof may inhibit the activity of CD73 upon binding thereto, e.g., the catalytic activity of converting AMP to adenosine.
In some embodiments, provided herein are anti-CD 73 monoclonal antibodies, or antigen-binding fragments thereof, comprising a heavy chain variable domain (VH) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 (NYWIH), SEQ ID NO 10 (NYWMH), SEQ ID NO 18 (SYWIN), SEQ ID NO 26 (NYGIS), SEQ ID NO 34 (SYWIN), SEQ ID NO 42 (NYGAT), SEQ ID NO 50 (SYGIN), SEQ ID NO 58 (GYYH), SEQ ID NO 66 (SYAMS), SEQ ID NO 74 (RYGIH) or SEQ ID NO 82 (GYYH) or a variant of HCDR1 comprising up to 3 (e.g. 1, 2 or 3) amino acid substitutions selected from the group consisting of SEQ ID NO 3 (YINPGDDYIKYSQNFKG), SEQ ID NO 11 (YINPSDAYTTYSQNFKG), SEQ ID NO 19 (NIYPGNSDTNNNEKFRN), SEQ ID NO 27 (EIYPGSGNTYYNEKFKD), SEQ ID NO 35 (NIYPGNSNTNYNEKFKS), SEQ ID NO 43 (EIYPGSGNAYYKENFKG), SEQ ID NO 51 (EIYPGSGNTYYNEKFKV), SEQ ID NO 59 (RINPYNGATTYNQNFKD), SEQ ID NO 67 (TISSGGSSTYYPDSVKG), SEQ ID NO 75 (VIWVGGSTNYNSTLMS) or SEQ ID NO 82 (e.g. 2 or 3 (e.g. 3) amino acid substitutions selected from the group consisting of SEQ ID NO 3 (YINPGDDYIKYSQNFKG), SEQ ID NO 11 (NIYPGNSDTNNNEKFRN), SEQ ID NO 27 (EIYPGSGNTYYNEKFKD), SEQ ID NO 35 (NIYPGNSNTNYNEKFKS), SEQ ID NO 43 (EIYPGSGNAYYKENFKG), SEQ ID NO 51 (RINPYNGATTYNQNFKD), SEQ ID NO 67 (9275) or SEQ ID NO 75 (VIWVGGSTNYNSTLMS (e.g. 2) amino acid substitutions selected from the group consisting of up to 3 (e.g. 2, 2 (e.2, 2 or 3) amino acid substitutions selected from the variant of amino acid substitutions selected from the group consisting of 1 (e.g. 3, and 3 (20) 28 (FDYSGYYYALDY), 36 (EGDTYSWYFDV), 44 or 105 (FDYIYYNGLEY or FDYIYYNALEY), 52 (NWDYYFDY), 60 (SIGSSPFDY), 68 (RGTTEVPHFDY), 76 (DGGITTVVADY) or 84 (SHYGSFDDY) or HCDR3 comprising Up to 3 (e.g., 1, 2, or 3) amino acid substitutions; the VL comprises a sequence selected from SEQ ID NOs: 6 (KASQDIKSYLS), SEQ ID NO 14 (KASQDIKSYLS), SEQ ID NO 22 (RASQSVSTSGYSYMH), SEQ ID NO 30 (KASQDLSTAVA), SEQ ID NO 38 (SASSSISSNYLH), SEQ ID NO 46 (KASQDVTTAVA), SEQ ID NO 54 (KASQDIKGYLG), SEQ ID NO 62 (KASQDINSYLS), SEQ ID NO 70 (KASQSVSNEAA), SEQ ID NO 78 (KASQDINSFLS) or SEQ ID NO 86 (KASQDINSYLS) LCDR1 or a variant of LCDR1 comprising up to 3 (e.g. 1, 2 or 3) amino acid substitutions selected from the group consisting of SEQ ID NO 7 (YATSLAD), SEQ ID NO 15 (YATDLAD), SEQ ID NO 23 (LASLNLKS), SEQ ID NO 31 (PASFLYT), SEQ ID NO 39 (GTSNLAS), SEQ ID NO 47 (SASHRY), SEQ ID NO 55 (YTNLAD), SEQ ID NO 63 (RGNWD), SEQ ID NO 71 (YANS), SEQ ID NO 79 (RAD) or SEQ ID NO 24 (e.g. 2 or 3), amino acid substitutions selected from the group consisting of at most 3 (YATSLAD), 15 (YATDLAD), SEQ ID NO 23 (LASLNLKS), SEQ ID NO 31 (PASFLYT), SEQ ID NO 39 (GTSNLAS), SEQ ID NO 39 (SLSLSLSLSLNO 47), SEQ ID NO 47 (SASHRY), SEQ ID NO 55 (RGNWD), SEQ ID NO 63 (RGNW), SEQ ID NO 71 (SEQ ID NO) or SEQ ID NO 31 (SEQ ID NO) or SEQ ID NO 32 (SEQ ID NO 32), or a variant of 1 (SEQ ID NO 32) comprising at most 3 (e.1, 48, 35 (SEQ ID NO) amino acid substitutions selected from the group consisting of 1 (SEQ ID NO 32 or 32) LCDR3 of SEQ ID NO. 72 (QQDYSSPWT), SEQ ID NO. 80 (LQYDELETYT) or SEQ ID NO. 88 (LQYDEFPYT) or a variant of LCDR3 comprising up to 3 (e.g. 1, 2 or 3) amino acid substitutions. In some embodiments, the anti-CD 73 antibody or antigen-binding fragment thereof is an inhibitor of CD73, and the enzymatic activity against cell surface expressed said CD73 has about 10 -1 μg/mL to about 10 -3 μg/mL IC 50 Values. In some embodiments, the anti-CD 73 antibody or antigen-binding fragment thereof is directed against an IC of the enzymatic activity of CD73 expressed on the cell surface 50 Value less than reference antibody MEDI9447 IC against CD73 50 Values. In some embodiments, the anti-CD 73 antibody or antigen-binding fragment thereof binds EC of cells expressing CD73 50 A value of about 1 μg/mL to about 10 -2 μg/mL (as detected by FASC). In some embodiments, the anti-CD 73 antibody or antigen-binding fragment thereof binds EC of cells expressing CD73 50 Values less than EC of reference antibody MEDI9447 binding to CD73 expressing cells 50 Values.
In some embodiments, the anti-CD 73 antibody or antigen-binding fragment thereof comprises HCDR3 selected from SEQ ID NO:4, 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, or 105 and LCDR3 selected from SEQ ID NO:8, 16, 24, 32, 40, 48, 56, 64, 72, 80, or 88, with amino acid substitutions occurring in the CDR1 and CDR2 domains of the VH and VL.
Thus, in some embodiments, provided herein are anti-CD 73 antibodies, or antigen-binding fragments thereof, the VH of which comprises a sequence selected from the group consisting of SEQ ID NOs: 2 (NYWIH), SEQ ID NO 10 (NYWMH), SEQ ID NO 18 (SYWIN), SEQ ID NO 26 (NYGIS), SEQ ID NO 34 (SYWIN), SEQ ID NO 42 (NYGAT), SEQ ID NO 50 (SYGIN), SEQ ID NO 58 (GYYH), SEQ ID NO 66 (SYAMS), SEQ ID NO 74 (RYGIH) or SEQ ID NO 82 (GYYH) or a variant of HCDR1 comprising up to 3 (e.g. 1, 2 or 3) amino acid substitutions selected from the group consisting of SEQ ID NO 3 (YINPGDDYIKYSQNFKG), SEQ ID NO 11 (YINPSDAYTTYSQNFKG), SEQ ID NO 19 (NIYPGNSDTNNNEKFRN), SEQ ID NO 27 (EIYPGSGNTYYNEKFKD), SEQ ID NO 35 (NIYPGNSNTNYNEKFKS), SEQ ID NO 43 (EIYPGSGNAYYKENFKG), SEQ ID NO 51 (EIYPGSGNTYYNEKFKV), SEQ ID NO 59 (RINPYNGATTYNQNFKD), SEQ ID NO 67 (TISSGGSSTYYPDSVKG), SEQ ID NO 75 (VIWVGGSTNYNSTLMS) or SEQ ID NO 82 (GYYH) or a variant of HCDR1 comprising up to 3 (e.g. 1, 2 or 3) amino acid substitutions selected from the group consisting of SEQ ID NO 19 (NIYPGNSDTNNNEKFRN), SEQ ID NO 27 (EIYPGSGNTYYNEKFKD (NIYPGNSNTNYNEKFKS), SEQ ID NO 43 (EIYPGSGNTYYNEKFKV), SEQ ID NO 51 (EIYPGSGNTYYNEKFKV), SEQ ID NO 59 (SEQ ID NO 59), SEQ ID NO 59 (37), SEQ ID NO 67) or SEQ ID NO 75 (37) or 3 (37) amino acid substitutions selected from the group consisting of 3 (37, 37 and 3 (37, 37 and 3 (37) amino acid substitutions HCDR3 of SEQ ID No. 44 or 105 (FDYIYYNGLEY or FDYIYYNALEY), SEQ ID No. 52 (NWDYYFDY), SEQ ID No. 60 (SIGSSPFDY), SEQ ID No. 68 (RGTTEVPHFDY), SEQ ID No. 76 (DGGITTVVADY) or SEQ ID No. 84 (SHYGSFDY); VL comprising LCDR1 selected from SEQ ID NO 6 (KASQDIKSYLS), SEQ ID NO 14 (KASQDIKSYLS), SEQ ID NO 22 (RASQSVSTSGYSYMH), SEQ ID NO 30 (KASQDLSTAVA), SEQ ID NO 38 (SASSSISSNYLH), SEQ ID NO 46 (KASQDVTTAVA), SEQ ID NO 54 (KASQDIKGYLG), SEQ ID NO 62 (KASQDINSYLS), SEQ ID NO 70 (KASQSVSNEAA), SEQ ID NO 78 (KASQDINSFLS) or SEQ ID NO 86 (KASQDINSYLS) or a variant of LCDR1 comprising up to 3 (e.g. 1, 2 or 3) amino acid substitutions selected from SEQ ID NO 7 (YATSLAD), SEQ ID NO 15 (YATDLAD), SEQ ID NO 23 (LASLKS), SEQ ID NO 31 (PASFLYT), SEQ ID NO 39 (GTSNLALAS), S EQ ID NO. 47 (SASHRY), SEQ ID NO. 55 (YTTNLAD), SEQ ID NO. 63 (RGNWLVD), SEQ ID NO. 71 (YASNRYS), SEQ ID NO. 79 (RAKLVD) or LCDR2 of SEQ ID NO. 87 (RANILID) or a variant of LCDR2 comprising up to 3 (e.g. 1, 2 or 3) amino acid substitutions, and LCDR3 selected from SEQ ID NO. 8 (LQYGDTTYT), SEQ ID NO. 16 (LQYGENTYT), SEQ ID NO. 24 (QHSRELPWT), SEQ ID NO. 32 (QQRYSTPYT), SEQ ID NO. 40 (QQGYILPFT), SEQ ID NO. 48 (QQHSSPPFT), SEQ ID NO. 56 (LQHGESPFT), SEQ ID NO. 64 (LQYDEFPNT), SEQ ID NO. 72 (QQDYSSPWT), SEQ ID NO. 80 (LQYDELYT) or SEQ ID NO. 88 (LQYDEFPYT). In some embodiments, the anti-CD 73 antibody or antigen-binding fragment thereof is an inhibitor of CD73, and the enzymatic activity against cell surface expressed said CD73 has about 10 -1 μg/mL to about 10 -3 μg/mL IC 50 Values. In some embodiments, the anti-CD 73 monoclonal antibody is directed against an IC of the enzymatic activity of said CD73 expressed on the cell surface 50 Value less than reference antibody MEDI9447 IC against CD73 50 Values. In some embodiments, the anti-CD 73 monoclonal antibody binds to EC of CD 73-expressing cells 50 A value of about 1 μg/mL to about 10 -2 μg/mL (as detected by FASC). In some embodiments, the anti-CD 73 antibody or antigen-binding fragment thereof binds EC of cells expressing CD73 50 Values less than EC of reference antibody MEDI9447 binding to CD73 expressing cells 50 Values.
In some embodiments, the amino acid substitutions referred to may be conservative amino acid substitutions. Conservative amino acid substitutions can generally be described as the substitution of one amino acid residue for another amino acid residue of similar chemical structure, with little or no effect on the function, activity, or other biological properties of the polypeptide. Conservative amino acid substitutions are well known in the art. Conservative substitutions may be, for example, the substitution of one amino acid in the following groups (a) - (e) with another amino acid within the same group: (a) small aliphatic nonpolar or low polar residues: ala, ser, thr, pro and Gly; (b) Polar negatively charged residues and (uncharged) amides: asp, asn, glu and Gln; (c) a polar positively charged residue: his, arg and Lys; (d) large aliphatic nonpolar residues: met, leu, ile, val and Cys; and (e) an aromatic residue: phe, tyr and Trp.
In some embodiments, provided herein are anti-CD 73 antibodies or antigen-binding fragments thereof (e.g., anti-CD 73 monoclonal antibodies), wherein 1) the VH comprises HCDR1, HCDR2 and HCDR3 of SEQ ID NOs 2, 3 and 4, respectively, and the VL comprises LCDR1, LCDR2 and LCDR3 of SEQ ID NOs 6, 7 and 8, respectively; 2) The VH comprises HCDR1, HCDR2 and HCDR3 of SEQ ID NO. 10, 11 and 12 respectively, and the VL comprises LCDR1, LCDR2 and LCDR3 of SEQ ID NO. 14, 15 and 16 respectively; 3) The VH comprises HCDR1, HCDR2 and HCDR3 of SEQ ID NO. 18, 19 and 20 respectively, and the VL comprises LCDR1, LCDR2 and LCDR3 of SEQ ID NO. 22, 23 and 24 respectively; 4) The VH thereof comprises HCDR1, HCDR2 and HCDR3 of SEQ ID NOs 26, 27 and 28 respectively, and the VL thereof comprises LCDR1, LCDR2 and LCDR3 of SEQ ID NOs 30, 31 and 32 respectively; 5) The VH comprises HCDR1, HCDR2 and HCDR3 of SEQ ID NOs 34, 35 and 36 respectively, and the VL comprises LCDR1, LCDR2 and LCDR3 of SEQ ID NOs 38, 39 and 40 respectively; 6) The VH comprises HCDR1, HCDR2 and HCDR3 of SEQ ID NO. 42, 43 and 44 respectively or HCDR1, HCDR2 and HCDR3 of SEQ ID NO. 42, 43 and 105 respectively, and the VL comprises LCDR1, LCDR2 and LCDR3 of SEQ ID NO. 46, 47 and 48 respectively; 7) The VH thereof comprises HCDR1, HCDR2 and HCDR3 of SEQ ID NOs 50, 51 and 52 respectively, and the VL thereof comprises LCDR1, LCDR2 and LCDR3 of SEQ ID NOs 54, 55 and 56 respectively; 8) The VH thereof comprises HCDR1, HCDR2 and HCDR3 of SEQ ID NOs 58, 59 and 60 respectively, and the VL thereof comprises LCDR1, LCDR2 and LCDR3 of SEQ ID NOs 62, 63 and 64 respectively; 9) The VH thereof comprises HCDR1, HCDR2 and HCDR3 of SEQ ID NOs 66, 67 and 68 respectively, and the VL thereof comprises LCDR1, LCDR2 and LCDR3 of SEQ ID NOs 70, 71 and 72 respectively; 10 VH comprising HCDR1, HCDR2 and HCDR3 of SEQ ID NOs 74, 75 and 76 respectively, VL comprising LCDR1, LCDR2 and LCDR3 of SEQ ID NOs 78, 79 and 80 respectively; or 11) its VH includes HCDR1, HCDR2 and HCDR3 of SEQ ID NOS 82, 83 and 84, respectively, and its VL includes LCDR1, LCDR2 and LCDR3 of SEQ ID NOS 86, 87 and 88, respectively.
In some embodiments, provided herein are anti-CD 73 antibodies or antigen-binding fragments thereof (e.g., anti-CD 73 monoclonal antibodies) comprising: 1) VH comprising the amino acid sequence shown in SEQ ID No. 1 and VL (9E 12E 3) comprising the amino acid sequence shown in SEQ ID No. 5; 2) VH comprising the amino acid sequence shown in SEQ ID No. 9 and VL (22E 1E 4) comprising the amino acid sequence shown in SEQ ID No. 13; 3) VH comprising the amino acid sequence shown in SEQ ID No. 17 and VL comprising the amino acid sequence shown in SEQ ID No. 21 (35D 8G 8); 4) VH comprising the amino acid sequence shown in SEQ ID No. 25 and VL (52 A8B 3) comprising the amino acid sequence shown in SEQ ID No. 29; 5) VH comprising the amino acid sequence shown in SEQ ID No. 33 and VL (52 A6B 3) comprising the amino acid sequence shown in SEQ ID No. 37; 6) VH comprising the amino acid sequence shown in SEQ ID No. 41 and VL comprising the amino acid sequence shown in SEQ ID No. 45 (96 A5); 7) VH comprising the amino acid sequence shown in SEQ ID No. 49 and VL (100C 5 A3) comprising the amino acid sequence shown in SEQ ID No. 53; 8) VH comprising the amino acid sequence shown in SEQ ID No. 57 and VL (134D 2H 6) comprising the amino acid sequence shown in SEQ ID No. 61; 9) VH comprising the amino acid sequence shown in SEQ ID No. 65 and VL (141G 7E 9) comprising the amino acid sequence shown in SEQ ID No. 69; 10 VH comprising the amino acid sequence shown in SEQ ID No. 73 and VL (143E 5D 2) comprising the amino acid sequence shown in SEQ ID No. 77; or 11) a VH comprising the amino acid sequence shown as SEQ ID NO. 81 and a VL (143H 3C 5) comprising the amino acid sequence shown as SEQ ID NO. 85.
In some embodiments, an anti-CD 73 antibody or antigen-binding fragment thereof (e.g., an anti-CD 73 monoclonal antibody) is provided that comprises: 1) VH comprising an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence set forth in SEQ ID No. 1 and VL comprising an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence set forth in SEQ ID No. 5; 2) VH comprising an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence set forth in SEQ ID No. 9 and VL comprising an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence set forth in SEQ ID No. 13; 3) VH comprising an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence set forth in SEQ ID No. 17 and VL comprising an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence set forth in SEQ ID No. 21; 4) VH comprising an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence set forth in SEQ ID No. 25 and VL comprising an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence set forth in SEQ ID No. 29; 5) VH comprising an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence set forth in SEQ ID No. 33 and VL comprising an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence set forth in SEQ ID No. 37; 6) VH comprising an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence set forth in SEQ ID No. 41 and VL comprising an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence set forth in SEQ ID No. 45; 7) VH comprising an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence set forth in SEQ ID No. 49 and VL comprising an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence set forth in SEQ ID No. 53; 8) VH comprising an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence set forth in SEQ ID No. 57 and VL comprising an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence set forth in SEQ ID No. 61; 9) VH comprising an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence set forth in SEQ ID No. 65 and VL comprising an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence set forth in SEQ ID No. 69; 10 VH comprising an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence set forth in SEQ ID No. 73 and VL comprising an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence set forth in SEQ ID No. 77; or 11) a VH comprising an amino acid sequence having at least 80% (e.g. at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence set forth in SEQ ID NO:81 and a VL comprising an amino acid sequence having at least 80% (e.g. at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence set forth in SEQ ID NO: 85.
In some embodiments, the anti-CD 73 antibody or antigen-binding fragment thereof (e.g., an anti-CD 73 monoclonal antibody) is a murine, chimeric, human, or humanized antibody.
The CDRs described above can be combined in various pairs to produce some humanized anti-CD 73 antibodies. Humanized alternatives are known to those skilled in the art. For example, potential can be determined by comparing FR sequences of VH or VL from other species with corresponding FR sequences of one or more closely related human VH or VLThe humanized replacement amino acids used are then introduced into the VH or VL using methods known in the art (also described herein) for one or more such potentially useful humanized replacement amino acids. In some embodiments, humanized antibodies can be obtained by replacing all CDR sequences of a human antibody VH or VL (i.e., all CDR sequences between the four FR sequences of a human antibody) with murine CDR sequences. Typically, the heavy and light chains of an antibody are humanized simultaneously. The resulting humanized antibodies can be tested for binding affinity to CD73, binding stability, and/or other desirable properties, such as inhibition of CD73 activity. The anti-CD 73 antibodies or antigen-binding fragments thereof provided herein may be partially or fully humanized. Preferably, the resulting humanized antibody, e.g., humanized antibody or antigen binding fragment thereof, binds CD73 with KD, EC as described herein 50 Or IC (integrated circuit) 50 Values.
In some embodiments, provided herein are anti-CD 73 humanized antibodies or antigen-binding fragments thereof, the VH of which comprises the amino acid sequence of any one of SEQ ID NOs 89, 91, 93, 95, 97, 99, and 101 or an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs 89, 91, 93, 97, 99, and 101, and the VL of which comprises the amino acid sequence of any one of SEQ ID NOs 90, 92, 94, 96, 98, 100, and 102 or an amino acid sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs 90, 92, 94, 96%, 98%, and 102. In some embodiments, the anti-CD 73 humanized antibody or antigen binding fragment thereof has about 10 for the enzymatic activity of cell surface expressed said CD73 -1 μg/mL to about 10 -2 μg/mL IC 50 Values. In some embodiments, the anti-CD 73 humanized antibody or antigen-binding fragment thereof binds CD73 with a KD value of about 10 -8 M to about 10 -11 M。
In some embodiments, provided herein are anti-CD 73 humanized antibodies or antigen binding fragments thereof comprising: 1) VH of the sequence shown in SEQ ID No. 89 and VL of the sequence shown in SEQ ID No. 90 (humanized 9E12E 3); 2) VH of the sequence shown in SEQ ID No. 91 and VL of the sequence shown in SEQ ID No. 92 (humanized 35D8G 8); 3) VH of the sequence shown in SEQ ID No. 93 and VL of the sequence shown in SEQ ID No. 94 (humanized 52A6B 3); 4) VH of the sequence shown in SEQ ID No. 95 and VL of the sequence shown in SEQ ID No. 96 (humanized 96 A5); 5) VH of the sequence shown in SEQ ID No. 97 and VL of the sequence shown in SEQ ID No. 98 (humanized 134D2H 6); 6) VH of the sequence shown in SEQ ID No. 99 and VL of the sequence shown in SEQ ID No. 100 (humanized 143E5D 2); or 7) a VH of the sequence shown in SEQ ID NO:101 and a VL (humanized 22E1B4 VL) of the sequence shown in SEQ ID NO: 102.
In some embodiments, an anti-CD 73 humanized antibody or antigen-binding fragment thereof provided herein further comprises an immunoglobulin constant region sequence. The immunoglobulin constant region may be selected from the group consisting of IgG1, igG2, or IgG4. In some embodiments, the anti-CD 73 humanized antibody or antigen-binding fragment thereof comprises a human IgG1 constant region sequence. In some embodiments, the heavy chain of the CD73 humanized antibody or antigen binding fragment thereof comprises a human IgG1 heavy chain constant region sequence and the light chain of the CD73 humanized antibody or antigen binding fragment thereof comprises a human Kappa chain constant region. The human IgG1 heavy chain constant region sequence can be the amino acid sequence shown in SEQ ID NO. 103 and the human Kappa chain constant region can be the amino acid sequence shown in SEQ ID NO. 104.
In some embodiments, provided herein are anti-CD 73 antibodies that competitively bind to CD73 (i.e., a "competing anti-CD 73 antibody") with any of the anti-CD 73 antibodies provided above, or antigen-binding fragments thereof. In some embodiments, the competitive anti-CD 73 antibody competes with any one of the anti-CD 73 antibodies provided above, or an antigen binding fragment thereof, for binding to the same epitope on CD 73. Such competitive binding may be detected, for example, by an ELISA assay.
The anti-CD 73 antibodies described herein (e.g., anti-CD 73 monoclonal antibodies) can be prepared using any method known in the art or as described herein.
Rodent monoclonal antibodies can be obtained by methods known in the art, such as by immunizing a rodent (e.g., a mouse or rat) and obtaining hybridomas therefrom, or by cloning Fab fragments or libraries of single chain Fc (scFv) using molecular biological techniques known in the art, followed by ELISA screening or selection using phage display. For recombinant production of monoclonal antibodies, the nucleic acid encoding the monoclonal antibody is isolated or synthesized and inserted into a replicable vector for further cloning (amplification of the DNA) or expression. DNA encoding the monoclonal antibodies can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibodies). Many vectors are available. The choice of vector will depend in part on the host cell to be used. In general, the host cell may be a prokaryotic cell or a eukaryotic cell (e.g., a mammalian cell).
anti-CD 73 antibody constructs
In another aspect, the present application provides an isolated polynucleotide encoding the above antibody or antigen binding fragment thereof. The nucleic acid molecules of the present application may be synthesized, for example, by standard chemical synthesis methods and/or recombinant methods, or semi-synthetically produced, for example, by combined chemical synthesis and recombinant methods. Ligation of the coding sequence to transcriptional regulatory elements and/or to other amino acid coding sequences may be performed using established methods such as restriction digestion, ligation, and molecular cloning. As is well known to those skilled in the art, altering (e.g., replacing, deleting, etc.) the nucleotide sequence encoding a protein does not alter the amino acids of the protein, such as by codon optimization, etc.
In yet another aspect, the present application provides an expression vector comprising the polynucleotide described above. Vectors known to those skilled in the art, such as plasmids, phage vectors or viral vectors. In some embodiments, the vector is a recombinant expression vector, such as a plasmid. These vectors include any element to support the function of their conventional expression vectors, including, for example, promoters, ribosome binding elements, terminators, enhancers, selectable markers, and origins of replication. The promoter may be a conventional promoter, an inducible promoter or an repressible promoter. Many expression vectors are known in the art that are capable of delivering nucleic acids into cells and can be used to produce antibodies or antigen binding fragments thereof within cells. According to the methods of embodiments of the present invention, conventional cloning techniques or artificial gene synthesis may be used to generate recombinant expression vectors.
In yet another aspect, the present application provides a host cell or cell-free expression system comprising the expression vector described above. Any host cell conventional in the art may be used in the present invention for expression of the antibody or antigen-binding fragment thereof. In some embodiments, the host cell is E.coli TG1 or BL21 (for expression of, e.g., scFv or Fab antibodies), CHO-DG44, CHO-3E7, CHO-K1 or HEK293. According to specific embodiments, the recombinant expression vector is transfected into a host cell by conventional methods (e.g., chemical transfection, thermal transfection, or electrotransfection) and stably integrated into the host cell genome, thereby allowing efficient expression of the recombinant nucleic acid. The cell-free expression system is a novel protein preparation system which is different from the traditional protein expression system, uses DNA or mRNA as a template, utilizes organelles in cell extracts, protein folding factors and other related enzyme systems, and realizes the in vitro body system of protein expression by adding amino acid, nucleotide, polymerase and energy substances.
Fusion proteins
In some embodiments, the antigen binding fragment of an anti-CD 73 antibody may be linked to an Fc fragment to form a fusion protein. The Fc fragment may be located at the C-terminus and N-terminus of the antigen binding fragment of the anti-CD 73 antibody. Preferably, the Fc fragment may be located at the C-terminus of the antigen binding fragment of the anti-CD 73 antibody. The fusion protein formed by the antigen binding fragment and the Fc fragment of the anti-CD 73 antibody has the capability of specifically binding to CD73 and has the effector functions of the Fc fragment, such as mediating complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), mediating phagocytosis and the like. In addition, fusion to the Fc fragment may increase the half-life of the antigen-binding fragment of the anti-CD 73 antibody in vivo, so as to increase the dosing interval when the antigen-binding fragment of the anti-CD 73 antibody is used as a therapeutic agent. In some embodiments, the Fc fragment may be derived from a constant region of an immunoglobulin, such as IgG1, igG2, or IgG4.
In some embodiments, the antigen binding fragment of an anti-CD 73 antibody may be linked to a protein tag to form a fusion protein. Protein tags may include purification tags and detectable tags. Purification tags include, but are not limited to, his6 tags, flag tags, MBP tags, GST tags, SUMO) tags, and the like. The detectable label may be used to indicate the presence or amount of the anti-CD 73 antibody or antigen-binding fragment thereof in the sample, or to provide information on the location of the anti-CD 73 antibody or antigen-binding fragment thereof in the subject's body or cell. Examples of detectable labels include various enzymes that can be used in immunoassays, such as horseradish peroxidase (HRP), alkaline phosphatase (ALP), and the like; fluorescent proteins, such as GFP. Because of the specific binding capacity of the anti-CD 73 antibody or antigen-binding fragment thereof to CD73, the amount of anti-CD 73 antibody or antigen-binding fragment thereof, and thus the amount of CD73 in the sample, can be determined by the amount of detectable label attached to the anti-CD 73 antibody or antigen-binding fragment thereof.
In other embodiments, the anti-CD 73 antibody or antigen-binding fragment thereof may be linked to a cytokine or therapeutic protein to form a fusion protein. In this case, the therapeutic effect of the cytokine or therapeutic protein can be achieved by targeted delivery of the cytokine or therapeutic protein to a specific tissue or cell by virtue of the specific binding capacity of the anti-CD 73 antibody or antigen binding fragment thereof to CD 73.
Multispecific antibodies
In some embodiments, provided herein are multispecific binding peptides that comprise at least one domain (or functional unit) that binds CD73 and one or more additional binding domains. The one or more additional binding domains may bind to a second antigen or protein other than CD 73.
In some embodiments, the multispecific antibody is a bispecific antibody.
In some embodiments, the first antigen binding domain of the bispecific antibody comprises an anti-CD 73 antibody, or antigen binding fragment thereof, provided herein, capable of specifically binding CD73; the second antigen binding domain is capable of specifically binding to an inhibitory immune checkpoint molecule, such as specifically binding CTLA-4, PD-L1, TIM-3 or LAG-3.
Thus, in one embodiment, the first antigen binding domain of the bispecific antibody is capable of binding CD73 and the second antigen binding domain is capable of binding CTLA-4. Preferably, the first antigen binding domain of the bispecific antibody is in the form of an scFv and the second antigen binding domain is in the form of an scFv or sdAb.
In one embodiment, the first antigen binding domain of the bispecific antibody is capable of binding CD73 and the second antigen binding domain is capable of binding PD-L1 or PD-1. Preferably, the first antigen binding domain of the bispecific antibody is in the form of an scFv and the second antigen binding domain is in the form of an scFv or sdAb.
For one embodiment, the first antigen binding domain of the bispecific antibody is capable of binding CD73 and the second antigen binding domain is capable of binding TIM-3. Preferably, the first antigen binding domain of the bispecific antibody is in the form of an scFv and the second antigen binding domain is in the form of an scFv or sdAb.
In one embodiment, the first antigen binding domain of the bispecific antibody is capable of binding CD73 and the second antigen binding domain is capable of binding LAG-3. Preferably, the first antigen binding domain of the bispecific antibody is in the form of an scFv and the second antigen binding domain is in the form of an scFv or sdAb.
In some embodiments, the first antigen binding domain of the bispecific antibody comprises an anti-CD 73 antibody, or antigen binding fragment thereof, provided herein, capable of specifically binding CD73; the second antigen binding domain is capable of specifically binding to a protein (enzyme or receptor) on the CD39-CD 73-adenosine pathway.
In one embodiment, the first antigen binding domain of the bispecific antibody is capable of binding CD73 and the second antigen binding domain is capable of binding CD39. Preferably, the first antigen binding domain of the bispecific antibody is in the form of an scFv and the second antigen binding domain is in the form of an scFv or sdAb.
In one embodiment, the first antigen binding domain of the bispecific antibody is capable of binding CD73 and the second antigen binding domain is capable of binding an adenosine 2A receptor (A2 AR). Preferably, the first antigen binding domain of the bispecific antibody is in the form of an scFv and the second antigen binding domain is in the form of an scFv or sdAb.
In some embodiments, the bispecific antibody further comprises an Fc fragment. The presence of an Fc fragment can conveniently form multimerization of the binding domain and can provide a related effector function.
Pharmaceutical compositions and methods of treatment
The specific binding capacity of the anti-CD 73 antibody or antigen-binding fragment thereof disclosed herein to CD73 is similar to that of the control antibody MEDI9447, and the binding capacity of a portion of the CD73 antibody or antigen-binding fragment thereof is superior to that of the control antibody MEDI9447. The anti-CD 73 antibodies or antigen-binding fragments thereof disclosed herein have similar CD73 inhibitory capacity to the control antibody MEDI9447, and partial anti-CD 73 antibodies or antigen-binding fragments thereof have superior inhibitory capacity to the control antibody MEDI9447.
The anti-CD 73 antibodies or antigen-binding fragments thereof disclosed herein, and fusion proteins or multispecific antibody molecules comprising the anti-CD 73 antibodies or antigen-binding fragments thereof, can be formulated with a pharmaceutically acceptable carrier into a pharmaceutical composition for administration to a subject for tumor prevention or treatment.
In some embodiments, an anti-CD 73 antibody or antigen-binding fragment thereof disclosed herein, or a fusion protein or multispecific antibody molecule comprising the anti-CD 73 antibody or antigen-binding fragment thereof, may be administered in combination with one or more other drugs (e.g., anti-tumor agents). In some embodiments, the antineoplastic agent may be a small molecule compound, such as a CD39 inhibitor, a CD73 inhibitor, or an A2AR inhibitor.
In some embodiments, the disease or disorder treated is a tumor, preferably a solid tumor. The solid tumor may be metastatic colorectal cancer, hormone refractory prostate cancer, melanoma, metastatic head and neck cancer, metastatic ovarian cancer, squamous cell carcinoma, and the like, particularly non-small cell lung cancer (NSCLC), triple Negative Breast Cancer (TNBC), pancreatic cancer, and the like. Any suitable method or route may be used to administer the anti-CD 73 antibodies or antigen-binding fragments thereof disclosed herein (as well as fusion proteins or multispecific antibody molecules comprising anti-CD 73 antibodies or antigen-binding fragments thereof), optionally in combination with other anti-neoplastic agents. Routes of administration include, for example, oral, intravenous, intraperitoneal, subcutaneous, or intramuscular administration.
Nucleic acid molecules encoding anti-CD 73 antibodies or antigen-binding fragments thereof, expression vectors comprising the same, and host cells transfected with the nucleic acid molecules or expression vectors may also be used for the therapeutic purposes described above in a variety of ways. For example, for expression vectors, therapeutic purposes may be achieved by introducing the expression vector into a subject by gene therapy means known in the art, expressing the protein or polypeptide of interest (anti-CD 73 antibody or antigen-binding fragment thereof, as well as fusion proteins or multispecific antibody molecules comprising anti-CD 73 antibody or antigen-binding fragment thereof).
The effective amount for this use may depend on the severity of the disease and the general state of the patient's autoimmune system. The dosing regimen will also vary with the disease state and subject state, and will generally range from a single bolus dose or continuous infusion to multiple doses per day (e.g., every 4-6 hours). A clinician skilled in the art can readily determine whether a subject is a candidate for such treatment, for example, by utilizing clinical trials, physical examinations, and subject family history.
Detection or treatment kit comprising anti-CD 73 antibody or antigen-binding fragment thereof
The anti-CD 73 antibodies or antigen-binding fragments thereof provided herein, and other forms of molecules (e.g., fusion proteins or bispecific antibody molecules) including anti-CD 73 antibodies or antigen-binding fragments thereof, can specifically bind to CD73 in a sample. The amount of CD73 (or the presence or absence) in a sample can be conveniently determined by detecting the amount of anti-CD 73 antibody or antigen-binding fragment thereof formed-CD 73 complex, or the amount of anti-CD 73 antibody or antigen-binding fragment thereof formed-CD 73 complex.
As described above, for this purpose, the anti-CD 73 antibodies or antigen-binding fragments thereof provided herein may be conjugated to various detection tags, facilitating detection by various means, including, but not limited to, bioluminescence, fluorescence, radiolabeling, product throughput of enzymatic reactions, and the like. After detecting the CD73 content in a sample, comparison with the normal CD73 content in a normal population can be used to determine the disease condition or severity of the subject providing the sample. The repeated detection of CD73 content change over time during the treatment of the subject can also be used to determine whether the treatment is effective, thereby providing a basis for modification of the treatment regimen.
The anti-CD 73 antibodies or antigen-binding fragments thereof provided herein, as well as other forms of molecules (e.g., fusion proteins or bispecific antibody molecules) comprising the anti-CD 73 antibodies or antigen-binding fragments thereof, can be placed in a container to form a detection fragment or therapeutic kit. These containers may be in the form of boxes, ampoules, vials, tubes, bags or suitable containers known in the art. These containers may be made of plastic, glass, laminated paper, metal foil, or other materials suitable for preserving pharmaceuticals. If desired, instructions for use are provided with the container. Instructions may generally include information about how to use the anti-CD 73 antibody or antigen-binding fragment thereof to bind to a peptide or a composition comprising the anti-CD 73 antibody or antigen-binding fragment thereof for treating or preventing a tumor (e.g., a solid tumor), e.g., may include descriptions of therapeutic agents (e.g., anti-CD 73 antibody or antigen-binding fragment thereof); dosage regimens for treating or preventing neoplasia (e.g., multiple myeloma); notice matters; a warning; indication; contraindications; adverse reactions; animal pharmacology; clinical study; and/or references. The instructions may be printed directly on the container (if present) or as a label affixed to the container or as a separate paper, book, card or folded print provided in or with the container.
EXAMPLE 1 preparation of anti-CD 73 monoclonal antibodies
Immunization with
According to current animal welfare regulations, 3 Balb/c and 3A/J mice were immunized with human CD73-HIS protein (R & D SYSTEMS, cat # 5795-EN). Antigen is dissolved in PBS solution or is immunized with CFA (Freund's complete adjuvant; primary immunization) or IFA (Freund's incomplete adjuvant; booster immunization) to form emulsion. In a series of immunization methods, the antigen is immunized by intraperitoneal injection or subcutaneous injection. Each animal received 4 doses (50 μg per mouse immunized with the first needle, then 25 μg per mouse in the next three needles). During immunization, 20. Mu.L of blood samples were collected from animals 7 days after each immunization time point, and serum antiserum titers were detected by ELISA method coated with hCD73 protein (R & D SYSTEMS, cat # 5795-EN) until fusion criteria were met. In the present invention, 5 mice (2 Balb/c mice and 3A-J mice) were high in serum titer for fusion.
Screening of hybridomas secreting anti-hCD 73 antibodies
Three days after the last immunization, spleen cells of selected mice were extracted and fused with sp2/0 cells in a sterile environment according to standard hybridoma-producing protocols. The fused cells were cultured in DMEM medium containing 1×hat (hypoxanthine, aminopterin, thymidine) and 10% fetal bovine serum for 6 days. In the present invention, a total of 160 96-well plate hybridomas were screened. All hybridoma supernatants were assayed for binding capacity to human CD73 by ELISA. Positive clones were screened against human CD73 according to ELISA signal (OD 450). In the present invention, 408 anti-hCD 73 hybridomas (ELISA OD > 2.0) produced from A-J mice and 62 anti-hCD 73 hybridomas (ELISA OD > 0.3) produced from Balb/c mice were selected by ELISA, and then their binding ability to CHO-K1 stable cell lines overexpressing human CD73 was examined by flow cytometry, and a total of 159 hybridomas bound to cell surface hCD73, and these parental hybridomas were subcloned by limiting dilution. Mu.l of the cell suspension was diluted to 1-3 cells/well and incubated in DMEM medium containing 1 XHAT (hypoxanthine, aminopterin, thymidine) and 10% fetal bovine serum. After 1 week of cell culture, a new round of screening was performed using ELISA and FACS until positive monoclonal was obtained. Each unique clone was selected for production of 0.5mg hybridoma purified antibodies for further identification. A total of 124 positive monoclonal were selected for antibody production and purification, and antibody affinity assays were performed by ELISA (table 1). Antibody isotypes were detected (Clonotyping System-HRP, southernBiotech; birmingham, AL), purified using Protein-A magnetic beads (GenScript, cat#L 00695), eluted with 0.5M sodium citrate solution (pH 3.5) and neutralized with 0.5M Tris-HCl (pH 9.0). The storage buffer was changed to PBS and the concentration was determined using nanodrags (thermofilter, cat#ND-ONE-W).
TABLE 1 binding signals of antibodies to CD73 in 124 monoclonal supernatants measured by ELISA
Example 2 characterization of anti-hCD 73 mouse antibody
In vitro functional assay of anti-CD 73 mouse antibodies
Functional assays of anti-CD 73 mouse antibodies are based on the activity of Calu-6 cell surface CD73 enzyme, which can reflect true post-translational modifications in non-small cell lung cancer (NSCLC) cells. Promega kit (CellTiter was usedKit, catalog #: g7571 anti-CD 73 mouse antibody function assay to inhibit Calu-6 cell surface CD73 enzymatic activity. It is known that excessive amounts of AMP can block ATP-dependent luciferase activity, and CD73 on Calu-6 cells can decompose AMP into adenosine and inorganic phosphate, which can enhance luciferase activity and emit light. Thus, antibodies that block CD73 enzymatic activity will reduce light emission. A total of 124 antibodies of 1. Mu.g/ml were tested for their ability to antagonize the activity of the CD73 protein. Antibodies with single dose inhibition greater than 50% were selected for multi-dose inhibition assays and IC50 assays. Briefly, calu-6 cells (ATCC, catalog number: HTB-56) TM ) Inoculated into 96-well dishes and incubated overnight at 37 ℃. The original medium was then replaced with fresh medium containing different concentrations of anti-CD 73 antibody and added to the corresponding wells of the culture plate. The assay plates were incubated at room temperature for 30 minutes. To detect CD73 activity, AMP solution was added to the cells, followed by 37℃C Incubate for 2 hours. To quantify AMP (SIGMA), culture supernatants were transferred to another 96-well assay plate and 100 μm ATP (SIGMA) was added to the corresponding wells. After 5-10 minutes incubation at room temperature, cellTiter Glo solution was added to 96-well assay plates, gently mixed with Phrastar (BMG LABECH, GR 18010766) and the assay plate data read. The inhibitory effect of the antibodies depends on the amount of AMP. Atp+amp represents maximum luciferase inhibition (100%), atp+amp+cd73 represents no luciferase inhibition (0%). The equation for the residual CD73 activity is shown below:
residual cd73 activity= ((atp+amp+cd73+abs) - (atp+amp)/(atp+amp+cd73) - (atp+amp)) ×100
The formula for anti-CD 73 antibody inhibitory activity is as follows:
inhibition ratio% (anti-CD 73 antibody activity) = (1- ((atp+amp+cd73+abs) - (atp+amp)/(atp+amp+cd73) - (atp+amp)) × 100
IC of 20 anti-CD 73 antibodies to CD73 protein was co-detected by Calu-6 cells 50 (half of the maximum inhibitory concentration), 8 antibodies showed inhibitory capacity comparable to or better than MEDI9447, including 52A6B3, 52A8B3, 96A5, 100C5A3, 134D2H6, 141G7E9, 143E5D2, and 143H3C5 (see fig. 1-3). To determine binding of antibodies to cross species CD73, 20 anti-CD 73 antibodies were tested by flow cytometry for expression of human (Probio, cat# RD 00783), cynomolgus monkey (Probio, cat# RD 00783) and mouse CD73 (Probio, cat# RD 00783) CHO cells (ATCC, cat# CCL-61) TM ) Is a combination of (a) and (b). Three antibody leads 9E12E3, 22E1B4 and 35D8G8 bind CD73 of mouse and cynomolgus origin (data not provided), and are shown in FIGS. 4 and Table 2 as an IC for Calu-6 cell surface CD73 activity 50 Value, IC of three antibodies binding CD73 activity 50 Comparable to MEDI-9447. The 11 mouse antibodies (including 9E12E3, 22E1E4, 35D8G8, 52A6B3, 52A8B3, 96A5A5, 100C5A3, 134D2H6, 141G7E9, 143E5D2 and 143H3C 5) were sequenced. The VH, VL and CDR amino acid sequences of these anti-CD 73 antibodies are listed in table 3.
FACS detection of binding of murine antibodies to human CD73+/CHO-K1 overexpressing cells
To verify binding of antibodies to cell surface antigensAbout 1X 10 5 CHO-K1 cells (ATCC, cat No: CCL-61) overexpressing human CD73 (Probio, cat No: RD 00783) TM ) The reaction was performed, followed by serial 3-fold dilution of the anti-CD 73 monoclonal antibody (45 to 7.6X10 -4 mu.g/mL) was incubated with cells, followed by staining with 1. Mu.g/mL of fluorophore (iFluor 647) -labeled goat anti-mouse IgG (H+L) secondary antibody. Binding affinity was expressed as average fluorescence intensity as shown in fig. 5. EC of antibodies 52A6B3, 52A8B3, 96A5, 100C5A3 and 134D2H6 50 Below MEDI9447, it shows a better binding capacity than MEDI 9447. While 141G7E9, 143E5D2 and 143H3C5 EC 50 Above MEDI9447. Table 4 lists EC for all antibodies 50 。
TABLE 2 IC of anti-CD 73 mouse antibodies to human CD73 on the surface of Calu-6 cells 50
Cloning IC 50 (μg/ml) Cloning IC 50 (μg/ml)
9E12E3 0.0444 100C5A3 0.0122
22E1B4 0.0216 134D2H6 0.0041
35D8G8 0.0209 141G7E9 0.0044
52A6B3 0.0097 143E5D2 0.0105
52A8B3 0.0165 143H3C5 0.0145
96A5A5 0.0055 MEDI9447 0.0142～0.0182
TABLE 3 VH, VL and CDR amino acid sequences of 11 anti-CD 73 mouse antibodies
/>
/>
Table 4: EC of FACS binding data for anti-CD 73 mouse monoclonal antibody 50
Cloning EC 50 (μg/ml) Cloning EC 50 (μg/ml)
52A6B3 0.0960 141G7E9 0.956
52A8B3 0.0459 143E5D2 0.609
96A5A5 0.0503 143H3C5 0.254
100C5A3 0.136 Mouse IgG NA
134D2H6 0.0718 MEDI9447 0.157
EXAMPLE 3 preparation and analysis of humanized antibodies
Humanized design of candidate antibodies
Based on the antibody variable domain sequences, CDRs, HV loops and FRs were analyzed and homology modeling was performed to obtain model structures of mouse antibodies. The solvent accessible surface area of the backbone residue was calculated and, based on the results, the buried backbone amino acid residue was determined (instant solvent accessible surface area < 15%). A human receptor for VH and VL was selected which has the same top sequence as the mouse counterpart. The CDRs of the mouse antibody were grafted directly onto the Human acceptor framework (Human-IgG 1) to obtain the sequence of the grafted antibody without any reverse mutation, with some amino acids reverted to the mouse framework sequence. Seven clones, including 9E12E3, 35D8G8, 52A6B3, 96A5, 134D2H6, 143E5D2, 22E1B4, were all successfully humanized. The amino acid sequences are shown in Table 5 (the constant region sequences used are shown in SEQ ID NOS: 103 and 104).
DNA sequences encoding humanized light and heavy chains were synthesized, pcDNA3.4 was introduced, and transfected into an Expi293F cell (Genscript Probio, catalog number: SC 1975) to produce antibody proteins.
Comparing antibody properties to MEDI-9447
Humanized antibodies were compared to homologous mouse antibodies by Surface Plasmon Resonance (SPR) using Biacore 8K (cytova, cat# 29125379). Briefly, mouse and human antibodies were affinity captured by binding to protein A via the sensor chip protein A (Cytiva, cat#: 29127555). Human CD73 CED protein (R & D SYSTEMS, cat # 5795-EN) was in the mobile phase using a 1:1 binding model for binding and dissociation. The associated contact time was 120 seconds, the separation contact time was 360 seconds, and the flow rate was 30. Mu.l/min. The results of the antibody-antigen binding affinity are shown in table 6, and the binding affinity of the antibodies after humanization to CD73 was comparable to that of murine antibodies.
IC of seven humanized anti-CD 73 antibodies to CD73 protein on Calu-6 cells was tested in total 50 (half of the maximum inhibitory concentration) the specific method was the same as that of the in vitro function test method of the anti-CD 73 mouse antibody of example 2, and the measurement results are shown in FIGS. 6A and 6B. Tables 7 and 8 (two experimental results) list the ICs of all humanized anti-CD 73 antibodies 50 Values. Of the seven humanized antibodies, humanized 96A5 and 56A6B3 showed better inhibition of CD73 activity than MEDI-9447, and humanized 134D2H6 and 143E5D2 lost inhibition of CD73, although the binding affinity of both antibodies to human CD73 ECD protein was not reduced.
TABLE 5 VH, VL and CDR amino acid sequences of seven humanized anti-CD 73 antibodies
/>
TABLE 6 affinity of humanized antibodies for binding to CD73-ECD
/>
TABLE 7 IC50 of humanized anti-CD 73 antibodies
Cloning IC 50 (μg/ml)
MEDI-9447 0.0281
Humanized 9E12E3 0.3610
Humanized 35D8G8 0.0456
Humanized 52A6B3 0.0275
Humanized 134D2H6 0.1245
Humanized 143E5D2 NA
TABLE 8 IC50 of anti-CD 73 humanized antibodies
The embodiments of the present invention are not limited to the examples described above, and those skilled in the art can make various changes and modifications in form and detail without departing from the spirit and scope of the present invention, which are considered to fall within the scope of the present invention.
Reference is made to:
1.Allard,D.,Immunology Letters(2018),https://doi.org/10.1016/j.imlet.2018.05.001.
2.Cancer Res.1997Jul 1；57(13):2602-5.
3.Oncoimmumology,2016,VOL.5,NO.8,e1208875,
http://dx.doi.org/10.1080/2162402X.2016.1208875.
4.Clinical trial information:NCT03454451.
5.Journal of Molecular Medicine(2019)97:803–815,
https://doi.org/10.1007/s00109-018-01742-0.
6.Jiang et al.BMC Cancer(2018)18:267,
https://doi.org/10.1186/s12885-018-4073-7.

Claims (19)

1. an isolated antibody or antigen-binding fragment thereof comprising a heavy chain variable domain (VH) comprising HCDR1, HCDR2 and HCDR3 having the sequences shown in SEQ ID NOs 34, 35 and 36 respectively, and a light chain variable domain (VL) comprising LCDR1, LCDR2 and LCDR3 having the sequences shown in SEQ ID NOs 38, 39 and 40 respectively; wherein the antibody or antigen binding fragment thereof is capable of specifically binding CD73.
2. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody is a murine antibody, chimeric antibody, humanized antibody, or human antibody.
3. The antibody or antigen-binding fragment thereof of claim 1 or 2, which is a monoclonal antibody, scFv, fab, fab ', (Fab') 2 Or Fv.
4. The antibody or antigen-binding fragment thereof of claim 2, wherein the VH of the humanized antibody comprises the amino acid sequence set forth in SEQ ID No. 93 and the VL of the humanized antibody comprises the amino acid sequence set forth in SEQ ID No. 94.
5. The antibody or antigen-binding fragment thereof of claim 4, wherein the humanized antibody has an enzymatic activity against the CD73 expressed on the cell surface of 10 -1 Mu g/mL to 10 -2 μg/mL IC 50 Values.
6. The antibody or antigen-binding fragment thereof of claim 4, wherein the KD for binding between the antibody or antigen-binding fragment thereof and the CD73 is 10 -8 M to 10 -11 M。
7. The antibody or antigen-binding fragment thereof of claim 1, wherein the VH and/or VL are linked to constant regions of an immunoglobulin.
8. The antibody or antigen-binding fragment thereof of claim 7, wherein the VH is linked to an IgG1 constant region.
9. A bispecific antibody comprising the antibody or antigen-binding fragment thereof of any one of claims 1-8 and a second antibody moiety.
10. The bispecific antibody of claim 9, wherein the second antibody moiety is capable of binding an antigen other than CD 73.
11. The bispecific antibody of claim 10, wherein the antigen different from CD73 is CD39, CTLA-4, PD-L1, TIM-3, LAG-3, or A2aR.
12. The bispecific antibody of claim 9 or 10, wherein the second antibody moiety is Fab, fab ', (Fab') 2 Fv, scFv or sdAb.
13. A polynucleotide encoding the antibody or antigen-binding fragment thereof of any one of claims 1-8 or the bispecific antibody of any one of claims 9-12.
14. A vector comprising the polynucleotide of claim 13.
15. A cell comprising the polynucleotide of claim 13 or the vector of claim 14.
16. A pharmaceutical composition comprising:
the antibody or antigen-binding fragment thereof of any one of claims 1-8, or the bispecific antibody of any one of claims 9-12; and
a pharmaceutically acceptable carrier.
17. The pharmaceutical composition of claim 16, further comprising one or more additional anticancer agents.
18. Use of the antibody or antigen-binding fragment thereof of any one of claims 1-8, the bispecific antibody of any one of claims 9-12, the polynucleotide of claim 13, the vector of claim 14, or the cell of claim 15 in the manufacture of a medicament for treating a solid cancer that expresses CD 73.
19. The use of claim 18, wherein the solid cancer is selected from non-small cell lung cancer, triple negative breast cancer or pancreatic cancer.
CN202310739625.9A 2022-08-12 2022-08-12 anti-CD 73 antibody or antigen fragment thereof and application thereof Active CN116903744B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310739625.9A CN116903744B (en) 2022-08-12 2022-08-12 anti-CD 73 antibody or antigen fragment thereof and application thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210965534.2A CN115991772B (en) 2022-08-12 2022-08-12 anti-CD 73 antibody or antigen fragment thereof and application thereof
CN202310739625.9A CN116903744B (en) 2022-08-12 2022-08-12 anti-CD 73 antibody or antigen fragment thereof and application thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202210965534.2A Division CN115991772B (en) 2022-08-12 2022-08-12 anti-CD 73 antibody or antigen fragment thereof and application thereof

Publications (2)

Publication Number Publication Date
CN116903744A CN116903744A (en) 2023-10-20
CN116903744B true CN116903744B (en) 2024-03-08

Family

ID=85994282

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202310736062.8A Active CN116769034B (en) 2022-08-12 2022-08-12 anti-CD 73 antibody or antigen fragment thereof and application thereof
CN202210965534.2A Active CN115991772B (en) 2022-08-12 2022-08-12 anti-CD 73 antibody or antigen fragment thereof and application thereof
CN202310739625.9A Active CN116903744B (en) 2022-08-12 2022-08-12 anti-CD 73 antibody or antigen fragment thereof and application thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202310736062.8A Active CN116769034B (en) 2022-08-12 2022-08-12 anti-CD 73 antibody or antigen fragment thereof and application thereof
CN202210965534.2A Active CN115991772B (en) 2022-08-12 2022-08-12 anti-CD 73 antibody or antigen fragment thereof and application thereof

Country Status (2)

Country Link
CN (3) CN116769034B (en)
WO (1) WO2024032777A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116769034B (en) * 2022-08-12 2024-01-02 南京蓬勃生物科技有限公司 anti-CD 73 antibody or antigen fragment thereof and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001472A (en) * 2014-11-10 2017-08-01 免疫医疗有限公司 There is specific binding molecule and application thereof to CD73
CN110240654A (en) * 2018-03-07 2019-09-17 复旦大学 In conjunction with the antibody-drug conjugates of CD73
CN112513089A (en) * 2018-11-12 2021-03-16 江苏恒瑞医药股份有限公司 anti-CD 73 antibody, antigen binding fragment thereof and application
WO2021227306A1 (en) * 2020-05-12 2021-11-18 普米斯生物技术(珠海)有限公司 Anti-cd73 antibody and use thereof
WO2021259199A1 (en) * 2020-06-22 2021-12-30 信达生物制药(苏州)有限公司 Anti-cd73 antibody and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY189836A (en) * 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
MX2018006973A (en) * 2015-12-09 2019-05-16 Corvus Pharmaceuticals Inc Humanized anti-cd73 antibodies.
EP3981790A4 (en) * 2019-06-06 2023-10-11 Jacobio Pharmaceuticals Co., Ltd. Binding molecule specific for cd73 and use of binding molecule
WO2020253568A1 (en) * 2019-06-19 2020-12-24 海正生物制药有限公司 Anti-cd73 antibody and application thereof
KR20220048026A (en) * 2019-08-21 2022-04-19 하버 바이오메드 (상하이) 컴퍼니 리미티드 Anti-CD73 Antibodies and Applications thereof
TW202124446A (en) * 2019-09-18 2021-07-01 瑞士商諾華公司 Combination therapies with entpd2 antibodies
AU2020384305A1 (en) * 2019-11-15 2022-06-30 Genzyme Corporation Biparatopic CD73 antibodies
JPWO2021241729A1 (en) * 2020-05-29 2021-12-02
CN111714642A (en) * 2020-06-18 2020-09-29 复旦大学 Application of CD73 antibody-drug conjugate
CN113045659B (en) * 2021-03-18 2022-03-18 上海近岸科技有限公司 anti-CD73 humanized antibodies
CN116769034B (en) * 2022-08-12 2024-01-02 南京蓬勃生物科技有限公司 anti-CD 73 antibody or antigen fragment thereof and application thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001472A (en) * 2014-11-10 2017-08-01 免疫医疗有限公司 There is specific binding molecule and application thereof to CD73
CN110240654A (en) * 2018-03-07 2019-09-17 复旦大学 In conjunction with the antibody-drug conjugates of CD73
CN112513089A (en) * 2018-11-12 2021-03-16 江苏恒瑞医药股份有限公司 anti-CD 73 antibody, antigen binding fragment thereof and application
WO2021227306A1 (en) * 2020-05-12 2021-11-18 普米斯生物技术(珠海)有限公司 Anti-cd73 antibody and use thereof
WO2021259199A1 (en) * 2020-06-22 2021-12-30 信达生物制药(苏州)有限公司 Anti-cd73 antibody and use thereof

Also Published As

Publication number Publication date
CN115991772A (en) 2023-04-21
WO2024032777A1 (en) 2024-02-15
CN116769034B (en) 2024-01-02
CN116903744A (en) 2023-10-20
CN116769034A (en) 2023-09-19
CN115991772B (en) 2023-09-01

Similar Documents

Publication Publication Date Title
CN106029697B (en) Canine antibodies with modified CH2-CH3 sequences
TWI708788B (en) Bispecific antibody
US20190321466A1 (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
WO2020098734A1 (en) Anti-tigit antibody and use thereof
WO2020098599A1 (en) Anti-cd73 antibody, antigen-binding fragment thereof and application thereof
WO2019091449A1 (en) Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof
WO2011059762A1 (en) Anti-egfr antibodies and their uses
EP3741777A1 (en) Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CN110431231A (en) Anti-CD 3 antibodies and molecule comprising the antibody
JP6786722B2 (en) New Antibodies Against Programmed Cell Death Protein (PD-1) and Their Uses
CN110790839A (en) anti-PD-1 antibody, antigen binding fragment thereof and medical application
WO2022228183A1 (en) Anti-siglec15 antibody, preparation method therefor and use thereof
JP2022521958A (en) Anti-PD-L1 antibody and its applications
WO2024032777A1 (en) Anti-cd73 antibody or antigen fragment thereof and use thereof
CN114773473A (en) anti-CD 39 antibody and preparation method and application thereof
US20220041749A1 (en) Antibodies specific to muc18
CA3105415A1 (en) Antibodies specific to folate receptor alpha
JP2023522365A (en) Anti-CD73 antibody and its use
US11673963B2 (en) CRTAM antibodies and methods of treating cancer
US20240018254A1 (en) Anti-cd73 antibody and use thereof
WO2021035174A1 (en) Anti-cd22 antibodies and uses thereof
CA3150462A1 (en) Anti-cd19 antibodies and uses thereof
WO2011161970A1 (en) Anti-pdgf receptor antibody
RU2807484C2 (en) Antibody to pd-1, its antigen-binding fragment and its pharmaceutical use
WO2023040940A1 (en) Use of pvrig/tigit binding protein in combination with immune checkpoint inhibitor in treatment of cancers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant